Overview: In this Q&A, Cell Process Development Scientist at AGC Biologics Cell and Gene Center of Excellence Sara Morlacchi, provides her expert analysis on the current state of the cell therapy space, the growth of the industry, and barriers for cost and accessibility. Sara and the team at the site recently helped a developer reach commercial approval with the FDA for their cell therapy product – Orchard Therapuetics’ Lenmeldy™.
Q: Cell therapies use a variety of immune and stem cells and are either autologous or allogeneic. Is there a common platform process for manufacturing that can be optimized to reflect the different starting points and sets of overarching challenges?
A: Cell therapy drug products offer a proven therapeutic approach with the potential to treat many life-threatening diseases through powerful modes of action. Those currently in clinical trials or with commercial…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Health network pledges millions to keep mental health graduates in the workforce
The program seeks to fill the gap in post-graduates who leave the profession. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Implantable Brain-Computer Interface Collaborative Community (iBCI-CC) to Drive Innovation in Neurotechnology
Mass General Brigham is establishing the Implantable Brain-Computer Interface Collaborative Community (iBCI-CC). This is the first Collaborative Community in the clinical neurosciences that has participation from the U.S. Food and Drug Administration (FDA). The Christopher […]
Patch May Successfully Treat Congenital Heart Defects
Using laboratory engineered tissue, scientists at the University of Colorado Anschutz Medical Campus have created a full thickness, biodegradable patch that holds the promise of correcting congenital heart defects in infants, limiting invasive surgeries and […]
